logo
logo

Ipsen Completes Acquisition Of Epizyme Expanding Its Portfolio In Oncology

Ipsen Completes Acquisition Of Epizyme Expanding Its Portfolio In Oncology

08/12/22, 3:35 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/FR.svgboulogne billancourt
Industry
pharmaceutical
health care
Regulatory News:

Company Info

Company
Ipsen
Location
Boulogne Billancourt, Ile-de-France, France
Company info
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen, excluding its Consumer HealthCare business, has around 4,500 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com. Tazverik® is a registered trademark of Epizyme.

Related People